The therapeutic effect of EZH2 inhibitors in targeting human papillomavirus associated cervical cancer
Article
Vidalina, D., Ghali, L., Kassouf, N., Li, S., Li, D. and Wen, X. 2025. The therapeutic effect of EZH2 inhibitors in targeting human papillomavirus associated cervical cancer. Current Issues in Molecular Biology. 47 (12), p. 990. https://doi.org/10.3390/cimb47120990
| Type | Article |
|---|---|
| Title | The therapeutic effect of EZH2 inhibitors in targeting human papillomavirus associated cervical cancer |
| Authors | Vidalina, D., Ghali, L., Kassouf, N., Li, S., Li, D. and Wen, X. |
| Abstract | High-risk human papillomavirus (HPV) is a crucial risk factor in the development of cervical cancer, where epigenetic modifications and epithelial–mesenchymal transition (EMT) processes have been implicated in cancer progression and metastasis. Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, is frequently overexpressed in HPV-associated cervical cancers and has been linked to tumour progression. However, there is still no consensus on the mechanisms of their action and their effectiveness on HPV-associated cancers. This study aimed to investigate whether EZH2 inhibitors (EPZ6438 and ZLD1039) can be effective in managing cervical cancer with less toxic effects than the conventional chemotherapeutic drug cisplatin. Proliferation assay and flow cytometry results showed that EZH2 inhibitors effectively induced apoptosis and arrested cells in G0/G1 phase in both HPV+ and HPV- cervical cancer cells. Both inhibitors downregulated the expression of EZH2 and HPV16 E6/E7 at mRNA and protein levels whilst upregulating expressions of p53 and Rb and epithelial markers. In summary, both EZH2 inhibitors showed therapeutic potential in comparison to cisplatin based on cellular and molecular readouts. Additionally, EPZ6438 showed a greater efficacy and higher sensitivity towards HPV+ cells, which was further supported by preliminary in vivo results from the chorioallantoic membrane assay. |
| Keywords | EZH2 inhibitor; HPV16; cervical cancer; epigenetics |
| Sustainable Development Goals | 3 Good health and well-being |
| Middlesex University Theme | Health & Wellbeing |
| Research Group | Centre for Investigative and Diagnostic Oncology |
| Publisher | MDPI |
| Journal | Current Issues in Molecular Biology |
| ISSN | |
| Electronic | 1467-3045 |
| Publication dates | |
| Online | 27 Nov 2025 |
| 27 Nov 2025 | |
| Publication process dates | |
| Submitted | 31 Oct 2025 |
| Accepted | 24 Nov 2025 |
| Deposited | 03 Dec 2025 |
| Output status | Published |
| Publisher's version | License File Access Level Open |
| Copyright Statement | © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| Digital Object Identifier (DOI) | https://doi.org/10.3390/cimb47120990 |
| PubMed Central ID | PMC12732196 |
| Web of Science identifier | WOS:001646262300001 |
| National Library of Medicine ID | 100931761 |
https://repository.mdx.ac.uk/item/30289q
Download files
29
total views13
total downloads9
views this month4
downloads this month